

# JFB et GP2A 2013

## Orateurs confirm

### Orateurs Confirmés

#### L11 - Computer assisted drug design of protein therapeutics



Dr Nicolas BAURIN  
(SANOFI-AVENTIS, Vitry sur Seine, France)

#### L05 - Développement d'un nucléotide antisens actif par voie orale pour le traitement des MICI



Dr Salvatore BELLINVIA  
(GIULIANI SPA, Milano, Italy)

#### L01 - From PPARg agonists to Selective PPARg Modulator (SPPARM): a long story!



Dr Catherine DACQUET  
(INSTITUT DE RECHERCHES SERVIER, Suresnes, France)

#### L04 - Nouvelles perspectives thérapeutiques dans les maladies inflammatoires intestinales



Prof. Pierre DESREUMAUX  
(UNIVERSITÉ LILLE 2, Lille, France)

#### L06 - Design and synthesis of aminosteroids and steroidal neuromuscular blocking agents



Prof. Xianming HU  
(WUHAN UNIVERSITY, Wuhan, Hubei, China)

#### L07 - L'oligomérisation des récepteurs couplés aux protéines G et complexes protéiques associés: de nouvelles opportunités pour le drug design



Dr Ralf JOCKERS  
(UNIVERSITÉ PARIS DESCARTES, Paris, France)

#### L09 - The dynamics of protein-DNA recognition in the telomere



Dr Charles LAUGHTON  
(UNIVERSITY PARK NOTTINGHAM, Nottingham, United Kingdom)

#### L08 - Structure, function and inhibition of human protein kinase CK2



Prof. Marc LE BORGNE  
(UNIVERSITÉ CLAUDE BERNARD LYON 1, Lyon, France)

#### L02 - Serendipity: facteur de diversité

# JFB et GP2A 2013

## Orateurs confirm




Prof. Benoit RIGO  
(HEI, Lille, France)

### L03 - Myéloperoxydase: cible thérapeutique dans les syndromes inflammatoires chroniques



Mr Pierre VAN ANTWERPEN  
(ULB, Bruxelles, Belgium)

### L10 - Dual regulation of estrogen receptor with novel selective estrogen receptor modulators (SERMs)



Prof. Haibing ZHOU  
(WUHAN UNIVERSITY, Wuhan, China)

## Communications orales

### OC03 - PEA reduces colon and systemic inflammation in mice models of crohn's disease

Ms Mireille AL HOUAYEK  
(UCL, Bruxelles, Belgium)

### OC05 - Novel development in coumarins as FXIIa inhibitors: Improvement of solubility

Mrs Charlotte BOUCKAERT  
(UNAMUR, Namur, Belgium)

### OC04 - Nouvelle voie de synthèse de derivés furo[3,2-b]pyridiniques à activité mélatoninergique

Ms Audrey COUHERT  
(ICOA, Orléans, France)

### OC10 - Design and synthesis of 2-indolyl-thieno[2.3-d]pyrimidinones as potential inhibitors of VEGFR2

Dr Stéphanie HESSE  
(UNIVERSITÉ DE LORRAINE, Metz, France)

### OC14 - An unusual borontribromide-mediated, one-pot bromination/cyclisation reaction. application to the synthesis of a highly strained cyclopenta[1,3]cycopropa[1,2-b]pyrrolizin-8-one

Mr Jean-Pierre JOURDAN  
(CERMN, Caen, France)

### OC02 - Dynamique du complexe CD1d-ligand: Hypothèse mécanistique sur le profil d'activation des iNKT

Mr Xavier LAURENT  
(INSTITUT DE CHIMIE PHARMACEUTIQUE ALBERT LESPAGNOL , Lille, France)

### OC01 - Acyl-benzothiazol-2-one: a privileged scaffold in the design of PPAR modulators

Dr Nicolas LEBEGUE  
(UNIVERSITÉ LILLE 2, Lille, France)

### OC08 - Discovery of highly potent, selective and safe reversers of BCRP-mediated multidrug resistance

Ms Florine LECERF-SCHMIDT  
(UJF, Grenoble, France)

### OC06 - Synthesis and evaluation of harmine derivatives as new cytostatic compounds on cancerous cells

# JFB et GP2A 2013

## Orateurs confirm

Mrs Celine MEINGUET  
(UNAMUR, Namur, Belgium)

### **OC11 - 1,4-dihydropyridines as antiproliferative and multidrug resistance reversal agents**

Mr Conor O'SHEA  
(TRINITY COLLEGE DUBLIN, Dublin, Ireland)

### **OC13 - Asymmetric synthesis of Rhodotorulic acid analogues with potential antibacterial activities**

Ms Marine PILLON  
(UNIVERSITÉ DE PICARDIE JULES VERNE, Amiens, France)

### **OC07 - Antiplasmodial SARs in 2-trichloromethylazaheterocyclic series**

Dr Nicolas PRIMAS  
(FACULTÉ DE PHARMACIE DE MARSEILLE, Marseille, France)

### **OC09 - Metalloprotease inhibitors targeting: new strategy for chondrosarcoma treatment**

Dr Magali VIVIER  
(UMR 990 INSERM, Clermont-Ferrand, France)